Ποια είναι η τιμή για Kexing Biopharm Co., Ltd. (688136)

Η τιμή για Kexing Biopharm Co., Ltd. (688136) είναι $3.13

Ποια είναι η κεφαλαιοποίηση αγοράς για Kexing Biopharm Co., Ltd. (688136)

Η κεφαλαιοποίηση αγοράς για Kexing Biopharm Co., Ltd. (688136) είναι $621.33M

Kexing Biopharm Co., Ltd. (688136) Τιμή και Κεφαλαιοποίηση Αγοράς

Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily involved in the exploration, manufacturing, and commercialization of advanced recombinant protein-based drugs and microbial preparations, serving both the Chinese domestic market and international clientele. The company strategically directs its research and development endeavors towards crucial medical areas, specifically focusing on antiviral therapies, oncology, immunology, hematological conditions, digestive system health, and degenerative diseases. Its extensive product lineup features diverse pharmaceutical solutions. This includes innovative recombinant human proteins such as interferon a1b, erythropoietin, and granulocyte stimulating factor. Additionally, their offerings encompass microbial formulations like Clostridium butyricum combined live bacteria powder, traditional Chinese patent medicines (e.g., Kehuang Capsule), and chemical drugs like Entecavir. Kexing Biopharm also provides cutting-edge biologics, including liraglutide (a human glucagon-like peptide-1), along with other specialized therapeutics such as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules. Established in 1989, the company's main operations are situated in Jinan, China.

Η τιμή για 688136	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$26,506.21 $621.33M	NVDA	$5.264T	+847,098.02%
$23,673.28 $621.33M	AAPL	$4.701T	+756,551.17%
$21,034.18 $621.33M	GOOG	$4.177T	+672,199.70%
$19,222.52 $621.33M	MSFT	$3.817T	+614,295.12%
$14,433.44 $621.33M	AMZN	$2.866T	+461,225.22%

Η τιμή για 688136

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$26,506.21 $621.33M